Vaccinia Virus News and Research

RSS

The vaccinia virus is the "live virus" used in the smallpox vaccine. It is a "pox"-type virus related to smallpox. When given to humans as a vaccine, it helps the body to develop immunity to smallpox. The smallpox vaccine does not contain the smallpox virus and it cannot cause smallpox.

Cyclosporine suppresses hepatitis C virus and increases the chance of a sustained virological response after liver transplantation

Liver transplant patients with hepatitis C virus (HCV) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination therapy. Cyclosporine also showed efficacy against Hepatitis C virus in vitro.

5 Jan 2006

Gleevec or similar drugs might be useful in preventing adverse side effects of smallpox vaccine

Mice given a relatively new cancer drug can survive an otherwise lethal dose of vaccinia virus, a relative of smallpox virus, report scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID).

27 Jun 2005

Vaccine targets tumors where they live

Vaccine strategies are being designed to battle cancer, but their use for metastatic melanoma is a challenge.

3 Jun 2005

No serious adverse events found with next-generation smallpox vaccine

Interim data from a phase I/II clinical trial of a next-generation vaccine for smallpox suggest that the vaccine may provide immunity and thus far the trial has been without any serious adverse events.

22 Mar 2005

FDA approves new smallpox vaccination

The U.S. Food and Drug Administration (FDA) has approved Vaccinia Immune Globulin Intravenous (VIGIV) - the first intravenous human plasma-derived product available to treat certain rare complications of smallpox vaccination.

20 Feb 2005

HHS awards contracts totaling more than $232 million to fund development of new vaccines against smallpox, plague and tularemia

United States Department of Health and Human Services has announced four new contracts totaling more than $232 million to fund development of new vaccines against three potential agents of bioterrorism: smallpox, plague and tularemia. The National Institute of Allergy and Infectious Diseases (NIAID), will administer the contracts.

8 Oct 2004

Discovery could pave the way to smallpox Immunity

A team of scientists led by a Howard Hughes Medical Institute (HHMI) international research scholar has discovered the immune system mechanism that causes some mice to be more susceptible to mousepox than others.

9 Jun 2004

Double-punch approach to vaccine design more effective

A study revealing new information about how viral proteins move between cells and alert the immune system suggests that a double-punch approach to vaccine design would make them more effective.

1 Jun 2004

Research tests the efficacy of a smallpox vaccine candidate known as LC16m8

When used as an aerosolized weapon, smallpox could be controlled by a new vaccine under study at Saint Louis University School of Medicine, according to new data.

27 May 2004

$20.7 million to make smallpox vaccine safer

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a five-year, $20.7 million grant to National Jewish Medical and Research Center to lead a consortium of academic medical centers trying to make smallpox vaccines safer for millions of people with atopic dermatitis, also known as eczema.

19 May 2004

Alternative vaccine to Dryvax for smallpox

Not everybody can safely be vaccinated against smallpox using the current FDA-approved vaccine. Scientists hope another study vaccine, now undergoing its first testing in the United States at Saint Louis University, will give a choice to people who can't be given the current vaccine, known as Dryvax®.

10 May 2004

Experimental smallpox DNA vaccine

In the first successful study of its kind, scientists have shown that a DNA-based vaccine for smallpox can protect nonhuman primates from monkeypox, a disease that resembles smallpox in humans.

27 Apr 2004

Scientists studying vaccinia virus, a relative of smallpox, have determined that a gene necessary for virus replication also has a key role in turning off inflammation

Scientists at the University of Illinois at Urbana-Champaign studying vaccinia virus, a close relative of smallpox, have determined that a gene necessary for virus replication also has a key role in turning off inflammation, a crucial anti-viral immune response of host cells.

6 Apr 2004